Direct Antiviral Agent Treatment of Chronic HCV Infection Results in Rapid Regression of Transient Elastography (Fibroscan®) and Validated Fibrosis Markers FIB-4 and APRI

Bachofner, Jacqueline; Valli, Piero V.; Kröger, Arne; Müllhaupt, Beat; Mertens, JC

doi:10.1016/s0168-8278(16)01402-1

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This difference in our opinion because of most of our CTP-B cases was (CTP-B7). AS regard Change in FIB-4 score, our results were in agreement with results of Bachofner et al, [18] treatment with DAAs regimens cause rapid regression of fibrosis markers as FIB-4 (3-6 months post-treatment), also was similar to results recorded by Chan et al, [19].The main cause of improvement in our opinion was an improvement in liver inflammation especially in patients who achieve an SVR. As regard change in ALT and AST over time in our study, there is a significant decrease in AST and ALT levels in both groups these results were in agreement with a study from Gentile et al, [ [23]who detected CTP-B patients displayed significantly higher level of anemia than those with compensated cirrhosis.…”

Section: Group I N=32supporting

confidence: 92%

Outcome of Decompensated Hepatitis C Virus Cirrhotic Patients Treated with Direct Acting Antiviral Drugs

Ahmed

Zagloul

Gomaa

2020

Zagazig University Medical Journal

View full text Add to dashboard Cite

Background: All oral direct-acting antivirals (DAAs) effectively treat chronic hepatitis C infection (HCV) and widely used for patients with compensated cirrhosis. However, data regarding their safety and efficacy in patients with decompensated cirrhosis are insufficient . The aim of this work was to test efficacy, safety and outcome of DAAs in the treatment of decompensated HCV related cirrhotic patients (CTP-B). Methods: prospective study among 62 chronic HCV cirrhotic patients, divided into two groups. Group I(the study group) included 32 patients with CTP-B treated for 12 weeks by sofosbuvir (SOF) 400 mg once daily plus Daclatasvir (DCV) 60 mg once daily plus Ribavirin (RBV) with initial dose 600 mg /day), while group II (the control group) included 30 patients with CTP-A treated by (SOF 400 mg once daily + DCV 60 mg once daily +RBV dosed according to body weight) for 12 weeks. According to the National Committee for control of viral hepatitis (NCCVH). Follow up after end of treatment (EOT) for 24weeks so the total period of the study 36 weeks Results: cases achieved SVR in Group I: 93.75% and in group II:100%, Liver parameters were improved from baseline to 24 weeks after end of treatment. The most common adverse effects were anemia, no patients died by the end of the study, but one case 3.1% in group I stopped treatment due to severe complications. Conclusion: Treatment with DAAs in patients with CTP-B is effective and safe, but patients remain at risk of life-threatening complications as HCC and liver-related morbidity.

show abstract

Section: Group I N=32supporting

confidence: 92%

Outcome of Decompensated Hepatitis C Virus Cirrhotic Patients Treated with Direct Acting Antiviral Drugs

Ahmed

Zagloul

Gomaa

2020

Zagazig University Medical Journal

View full text Add to dashboard Cite

show abstract

“…This study was a little bit superior to a study done by Bachofner and his colleagues who observed a reduction in APRI scores and Fib-4 index after HCV eradication by about 60.9% and 29.1% respectively [12]. Another study done by Bruno and colleagues in 2016 compared APRI score and Fib-4 index before treatment and 24 months post treatment in 84 chronic HCV patients, all of whom achieved SVR24 and 77.3% were cirrhotics.…”

Section: Discussionmentioning

confidence: 59%

Fibrosis Regression after Treatment with Daas

Mehrez¹

2017

GHOA

View full text Add to dashboard Cite

Background: HCV infection promote liver fibrogenesis by direct and indirect mechanisms through chronic inflammation. Successful HCV treatment was associated with significant improvement in liver histology. Non-invasive methods (like APRI score and Fib-4 index) for the evaluation of liver fibrosis have been developed and validated.Methods: Fib-4 index and APRI score were calculated for 50 Egyptian chronic HCV (genotype 4) patients who received sofosbuvir (400 mg once daily) plus simeprevir (150 mg once daily) for 12 weeks. The end-point was a sustained virological response at 12 (SVR12) weeks post treatment.Results: Baseline fibrosis stage showed a mean APRI score of 0.63188 and mean Fib-4 index of 1.97210. All patients had an end of treatment response with negative HCV RNA. Improvement in liver enzymes and platelet count was reflected on the regression of fibrosis after treatment with a significant reduction in levels of both APRI score and Fib-4 index. Conclusion:Fibrosis regression -assessed by non-invasive markers of fibrosisis achievable upon removal of the causative agent.

show abstract

Direct Antiviral Agent Treatment of Chronic HCV Infection Results in Rapid Regression of Transient Elastography (Fibroscan®) and Validated Fibrosis Markers FIB-4 and APRI

Cited by 2 publications

References 0 publications

Outcome of Decompensated Hepatitis C Virus Cirrhotic Patients Treated with Direct Acting Antiviral Drugs

Outcome of Decompensated Hepatitis C Virus Cirrhotic Patients Treated with Direct Acting Antiviral Drugs

Fibrosis Regression after Treatment with Daas

Contact Info

Product

Resources

About